Degradation and metabolism of mometasone furoate in humans: Influence of reversible, sequential metabolism, and ionic strength

Journal of Pharmaceutical Sciences

Volumn 93, Issue 12, 2004, Pages 2877-2880

  Davies, Neal M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CYTOCHROME P450 3A; DRUG RECEPTOR; ESTERASE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; MAGNESIUM CHLORIDE; MOMETASONE FUROATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

AQUEOUS SOLUTION; BINDING AFFINITY; BINDING KINETICS; CHROMATOGRAPHY; DISSOCIATION; DRUG BINDING; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIC STRENGTH; LUNG PARENCHYMA; MICROSOME; NOTE; STEROID HYDROXYLATION; VALIDATION PROCESS;

EID: 10644261385     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20189     Document Type: Note

References (20)

1. Valotis A, Neukam K, Elert O, Högger P. 2004. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 93:1337-1354.
2. Teng XW, Foe K, Brown KF, Cutler DJ, Davies NM. 2001. High-performance liquid Chromatographic analysis of mometasone furoate and its degradation products: Application to in vitro degradation studies. J Pharm Biomed Anal 26:313-319.
3. Teng XW, Cutler DJ, Davies NM. 2003. Degradation kinetics of mometasone furoate in aqueous systems. Int J Pharm (1-2):129-141.
4. Teng XW, Cutler DJ, Davies NM. 2003. Kinetics of metabolism and degradation of mometasone furoate in rat biological fluids and tissues. J Pharm Pharmacol 55:617-630.
5. Teng XW, Brown KF, Cutler DJ. 1999. Metabolism of mometasone furoate in subcellular fractions of human lung tissue. Proceedings of the Australasian Pharmaceutical Science Association (APSA) Annual Conference Perth, Australia P-36, 68.
6. Teng XW, Davies NM, Cutler DJ, Brown KF. 2000. Clinical and pre-clinical degradation and metabolism of mometasone furoate: Rat versus human. Proceedings of the Canadian Society of Pharmaceutical Sciences (CSPS) 3rd Annual Symposium Vancouver, Canada June 2000 A 25-1. http://www.ualberta.ca/~csps/J Pharm Pharm Sci 3(1)/Proceedings00.htm A 25-1.
7. Teng XW, Davies NM, Cutler DJ, Brown KF. 2000. Degradation of mometasone furoate in human and rat tissues and biological fluids. Proceedings of the Australasian Pharmaceutical Science Association (APSA) Annual Conference Newcastle Australia December. A16-P28.
8. Teng XW, Cutler DJ, Davies NM. 2002 1. Metabolism of mometasone furoate in human liver, intestine and lung. Canadian Society of Pharmaceutical Sciences 5th Annual, Canada. J Pharm Pharm Sci 5(2):A13-A89.
9. Teng XW, Davies NM, Cutler DJ, Tattam BN, Cheung HTA. 2002. Structural characterization of major degradation products and metabolite of mometasone furoate. Canadian Society of Pharmaceutical Sciences 5th Annual Symposium, Canada. J Pharm Pharm Sci 5(2):A14-A89.
10. Teng XW, Cutler DJ, Davies NM. 2002. Metabolism and degradation of mometasone furoate in rat and human biological fluids and tissues. American Association of Pharmaceutical Scientists Canada AAPS. Pharm Sci 4(4):A T2242.
11. Teng XW, Cutler DJ, Davies NM. 2003. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Disp 24:321-333.
12. Andersson P, Ryrfeldt A. 1984. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha, 21-dipropionate in human liver and lung homogenate. J Pharm Pharmacol 36:763-765.
13. Foe K, Brown KF, Seale JP. 2000. Comparative kinetics of metabolism of beclomethasone propionate esters in human lung homogenates and plasma. J Pharm Sci 89:1143-1150.
14. Zbaida S, Shannon D, Du Y, Lu X, Ng K, Chowdhury S, Blumenkrantz N, Patrick J, Cayen MN. 1997. In vitro metabolism of mometasone furoate (Abstract No. P339). FASEB J 11:(8 Suppl S). A829.
15. Yost GS. 1999. Sites of metabolism: Lung. In: Woolf TF, editor. Handbook of drug metabolism. New York: Marcel Dekker, Inc. pp 263-278.
16. Draper RW, Puar MS, Vater EJ, McPhail AT. 1998. An unusual dienone-phenol rearrangment product formed during the synthesis of mometasone furoate (SCh 32088). Steroids 63:135-140.
17. Draper RW, Hu B, McPhail AT, Puar MS, Vater EJ, Weber L. 1999. Unusual hydroxy-gamma-sultone byproducts of steroid 21-methanesulfonylation. An efficient synthesis of mometasone 17-furoate (Sch 32088). Tetrahedron 55:3355-3364.
18. Sahasranaman S, Issar M, Toth G, Horvath G, Hochhaus G. 2004. Characterization of degradation products of mometasone furoate. Pharmazie 59:367-373.
19. Isogai M, Shimizu H, Esumi Y, Teresawa T, Okasa T, Sugeno K. 1993. Binding affinities of mometasone furioate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol 44:141-145.
20. Valotis A, Hogger P. 2004. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res 22:5:1-7.